EXEL

Exelixis Inc.

Price

$54.39

return (12m)

44.96%

p/e

14.79

p/bv

6.90

DIVIDEND YIELD

0.00%

EXEL price

Exelixis

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment EXEL

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-2.63%

3 months

9.55%

1 year

44.96%

2 years

104.55%

5 years

194.96%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals EXEL

Valuation

P/E

14.79

Sector -4.38

Industry -4.38

P/BV

6.90

Sector 2.02

Industry 2.02

P/Revenue (PSR)

5.22

Sector -4.40

Industry -4.40

EV/EBITDA

46.54

Sector -263.09

Industry -263.09

EV/EBIT

47.84

Sector -702.90

Industry -702.90

P/EBITDA

12.47

Sector -4.39

Industry -4.39

P/EBIT

12.83

Sector -4.73

Industry -4.73

P/Total Assets

5.10

Sector 1.49

Industry 1.49

P/Net Current Assets

21.20

Sector -11.70

Industry -11.70

P/Working Capital

14.31

Sector -3.19

Industry -3.19

EPS

3.43

Sector -2.14

Industry -2.14

BVPS

7.35

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

96.48%

Sector 36.74%

Industry 36.74%

EBITDA Margin

40.62%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

39.51%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

40.72%

Sector -38.22%

Industry -38.22%

Net Profit Margins

35.33%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.25

Sector 0.03

Industry 0.03

Profitability

ROE

46.68%

Sector -65.14%

Industry -65.14%

ROA

34.50%

Sector -65.53%

Industry -65.53%

ROIC

49.67%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.46

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-3.29

Sector -6.07

Industry -6.07

Net Debt / EBIT

-3.38

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.46

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.74

Sector 0.41

Industry 0.41

Liabilities/Assets

0.26

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

11.16%

Sector -

Industry -

5Y Earnings CAGR

30.08%

Sector -

Industry -

FAIR VALUE OF Exelixis ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$54.39

Fair Value

$23.82

Upside Return potential.

-56.21%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals EXEL

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
EXEL Exelixis Inc.	$54.39	44.04%	0.00%	14.79	6.90	46.68%	35.33%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

EXEL Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Exelixis

Exelixis Inc.

Average Investor10 user rating

4.0 (2 people)

United States

32 years

Founded: 1994

2000

Time since IPO - 26 years

773

Employees

Exelixis Inc. (United States) is listed on the Nasdaq and has a market capitalization of $12.72 billion, with shareholders equity totaling $1.84 billion.

The company employs approximately 773 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Exelixis Inc. reported $2.44 billion in revenue, generating net income of $860.63 million.

Key financial metrics include a P/E ratio of 14.79, a price-to-book (P/B) ratio of 6.90, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker EXEL.

Market cap

$12.72 billion

Net worth

$1.84 billion

$1,843,760,000.00

Assets

$2.49 billion

$2,494,230,000.00

Total Shares Outstanding

251.00 million

251,000,000

Average Daily Trading Volume

$2.68 million

$2,682,406.00

Sector

Health Care

Industry

Biotechnology

EXEL

EXEL revenue and profits

Financial Results EXEL

DRAG THE FRAME TO SEE MORE DATA

EXEL cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Exelixis (EXEL) today?

A cotação de Exelixis (EXEL) hoje está em US$ 54.39, com uma variação de 44.96% em relação ao último ano. A cotação de Exelixis (EXEL) iniciou o ano negociando na casa dos US$ 43.83 e hoje está em US$ 54.39. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Exelixis (EXEL) e dados de ações do Ibovespa e mercados internacionais.

Quando Exelixis (EXEL) paga dividendos?

Exelixis (EXEL) não distribuiu dividendos no último ano.

Is Exelixis (EXEL) a good investment?

Atualmente, Exelixis (EXEL) está cotada a US$ 54.39, com um P/L de 14.79, representando um desvio de 2,243% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 44.96 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 44.96%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Exelixis (EXEL) stock?

Investir em ações de Exelixis (EXEL) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Exelixis (EXEL) yield today?

A rentabilidade de Exelixis (EXEL) foi de -2.63% no último mês, 44.96% no último ano e 194.96% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Exelixis (EXEL) hoje, o investimento total seria de US$ 5,439.00, com base na cotação atual de US$ 54.39.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 7,884.37
Em 5 anos: US$ 16,042.87
Em 10 anos: US$ 5,439.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

EXEL

Exelixis Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment EXEL

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING EXEL WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Exelixis

Exelixis Inc.

United States

32 years

2000

773

PROFIT X PRICE EXEL

Financial Results EXEL

EXEL cash flow

Asset, Revenue and Profit Growth - EXEL

EXEL balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions